Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab for eradication of minimal residual disease in chronic lymphocytic leukaemia
ISRCTN23153249Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 cohorts), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoints: Rate of achieving MRD negativity and Safety of alemtuzumab in the MRD-positive setting. Started Mar 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN23153249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN23153249.